IMBRUVICA has helped many adults with CLL/SLL live longer

In a clinical trial of 269 people, 8% of CLL patients on IMBRUVICA® (ibrutinib) died versus 16% taking a chemotherapy (chlorambucil), after 28 months of follow-up.1*

Here’s to more time together and the opportunity to keep doing what you love.

IMBRUVICA is a prescription medicine used to treat:

• Adults with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
• Adults with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with 17p deletion.
• Adults with Waldenström's macroglobulinemia (WM).
• Adults and children 1 year of age and older with chronic graft versus host disease (cGVHD) after failure of 1 or more lines of systemic therapy.

It is not known if IMBRUVICA® is safe and effective in children under 1 year of age.